Jasper Therapeutics, Inc. - Class A (JSPR) earnings
JSPR earnings moved a median of -2.43% by the close. Quarterly and annual JSPR reports and results, each read against the price at its own news timestamp. Back to the JSPR overview →
22 measured JSPR earnings events.
Where these JSPR earnings landedvs 22 measured JSPR earnings reactions
| Middle 50% of JSPR earnings reactions | -6.78% to +3.70% |
|---|---|
| Median reaction (to close) | -2.43% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 JSPR earnings events with a measured close landed between -6.78% and +3.70%; 36% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Jasper Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.45% | -5.51% | |
| Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | -0.63% | -5.50% | |
| Form 10-Q Jasper Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.11% | -7.20% | |
| Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | +0.11% | -7.20% | |
| Form 10-K/A Jasper Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -0.41% | -1.01% | |
| Form 10-K Jasper Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +3.62% | +2.44% | |
| Form 10-Q Jasper Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -3.11% | -7.77% | |
| Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | -3.11% | -7.77% | |
| Form 10-Q Jasper Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +1.68% | +4.12% | |
| Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | +1.68% | +4.12% | |
| Form 10-Q Jasper Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -1.11% | -2.43% | |
| Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | -1.11% | -2.43% | |
| Form 10-K Jasper Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +1.32% | +4.22% | |
| Form 10-Q Jasper Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -2.89% | -3.61% | |
| Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | -2.89% | -3.61% | |
| Form 10-Q Jasper Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -0.17% | +10.04% | |
| Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments | Press release | -0.17% | +10.04% | |
| Form 10-Q Jasper Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | — | -1.44% | |
| Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments | Press release | +0.00% | +1.50% | |
| Form 10-K Jasper Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -2.64% | +7.60% | |
| Form 10-Q Jasper Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -11.49% | -9.41% | |
| Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | -11.49% | -9.41% |
Keep exploring
More JSPR: analyst actions → · SEC filings → · JSPR overview →